Loading...
XKRX249420
Market cap224mUSD
Dec 27, Last price  
11,830.00KRW
1D
-1.00%
1Q
-15.98%
Jan 2017
-28.09%
IPO
-41.09%
Name

Il Dong Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:249420 chart
P/E
—
P/S
0.55
EPS
—
Div Yield, %
0.05%
Shrs. gr., 5y
2.57%
Rev. gr., 5y
3.58%
Revenues
600.76b
-5.80%
201,343,779,350460,650,814,930503,907,355,300517,467,681,610561,845,100,170560,131,626,310637,714,489,810600,757,839,590
Net income
-78.93b
L-44.48%
12,578,693,00019,841,042,00012,720,690,000-13,443,583,240-13,019,159,600-100,968,468,840-142,169,549,890-78,928,206,140
CFO
-36.62b
L-31.61%
19,156,880,41073,724,186,54066,646,835,05041,365,649,73019,365,601,510-11,365,958,110-53,540,653,960-36,615,397,150
Dividend
Dec 27, 201995.2381 KRW/sh

Profile

Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-histamine drugs, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, topical preparation, and urogenital system applications. It also provides raw material drugs; health foods and foods; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products. In addition, the company manages licenses and provides contract manufacturing services. It also exports its products to approximately 20 countries worldwide. Ildong Pharmaceutical Co., Ltd. a strategic collaboration with Evotec SE to accelerate the development of various Ildong's proprietary projects through access to Evotec's INDiGO platform. The company was founded in 1941 and is headquartered in Seoul, South Korea.
URL
https://www.ildong.com/
IPO date
Aug 31, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
600,757,840
-5.80%
637,714,490
13.85%
560,131,626
-0.30%
Cost of revenue
570,487,654
626,336,754
532,599,045
Unusual Expense (Income)
NOPBT
30,270,186
11,377,736
27,532,581
NOPBT Margin
5.04%
1.78%
4.92%
Operating Taxes
(13,311,684)
22,346,154
(40,236,573)
Tax Rate
196.40%
NOPAT
43,581,870
(10,968,418)
67,769,154
Net income
(78,928,206)
-44.48%
(142,169,550)
40.81%
(100,968,469)
675.54%
Dividends
(160,000)
(120,000)
Dividend yield
0.03%
0.02%
Proceeds from repurchase of equity
(1,817,194)
1,745,328
BB yield
0.37%
-0.22%
Debt
Debt current
181,246,518
148,361,007
134,435,071
Long-term debt
51,708,440
109,391,116
127,071,523
Deferred revenue
Other long-term liabilities
91,284,351
81,902,847
92,524,684
Net debt
129,491,360
184,211,307
103,488,413
Cash flow
Cash from operating activities
(36,615,397)
(53,540,654)
(11,365,958)
CAPEX
(18,188,383)
(19,605,370)
(19,790,141)
Cash from investing activities
(20,360,050)
(26,435,446)
(43,367,886)
Cash from financing activities
58,151,954
(3,287,179)
104,315,820
FCF
56,391,622
(53,855,250)
130,823,487
Balance
Cash
81,279,013
78,745,854
154,681,333
Long term investments
22,184,585
(5,205,039)
3,336,848
Excess cash
73,425,706
41,655,091
130,011,599
Stockholders' equity
913,617
(170,751,612)
(40,634,871)
Invested Capital
477,362,310
655,242,311
516,547,058
ROIC
7.70%
13.86%
ROCE
6.33%
2.35%
5.79%
EV
Common stock shares outstanding
27,030
26,344
23,785
Price
18,160.00
-36.39%
28,550.00
-15.03%
33,600.00
77.78%
Market cap
490,867,651
-34.73%
752,111,750
-5.89%
799,186,550
77.77%
EV
625,081,868
948,949,804
916,728,596
EBITDA
58,588,862
40,922,363
56,843,356
EV/EBITDA
10.67
23.19
16.13
Interest
14,724,607
9,787,843
10,556,461
Interest/NOPBT
48.64%
86.03%
38.34%